Nemluvio (nemolizumab-ilto) Letter of Medical Necessity
Nemluvio (nemolizumab) is an IL-31 receptor antagonist for prurigo nodularis and atopic dermatitis. Most payers place it behind Dupixent, so the Letter of Medical Necessity must document disease severity, topical failures, and why dupilumab failed, was not tolerated, or is not appropriate.
FDA-Approved Indications
- ● prurigo nodularis in adults
- ● moderate-to-severe atopic dermatitis in patients 12 years and older, with topical corticosteroids and/or calcineurin inhibitors
Why Nemluvio Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Step therapy: Dupixent (dupilumab) not tried first
- 2. Nodule count, IGA, or peak pruritus NRS not documented
- 3. Topical corticosteroid and calcineurin inhibitor trials not documented
- 4. Concurrent biologic or JAK inhibitor use
- 5. Prescriber is not a dermatologist
What to Include in a Nemluvio Letter of Medical Necessity
Document the diagnosis with nodule count, IGA, and worst-itch NRS for prurigo nodularis, or EASI, BSA, and IGA for atopic dermatitis. List topical corticosteroid and calcineurin inhibitor trials with potency, duration, and outcome, plus any dupilumab or JAK inhibitor history with reason for discontinuation. Explain the rationale for IL-31 targeting when itch is the dominant symptom.
Key clinical evidence to cite:
- ✓ OLYMPIA 1 and 2 Phase 3 trials — rapid itch and lesion improvement in prurigo nodularis
- ✓ ARCADIA 1 and 2 Phase 3 trials — improved EASI-75 and itch in atopic dermatitis with background topical therapy
- ✓ Targets IL-31, the primary itch cytokine, distinct from IL-4/IL-13 blockade
Relevant guidelines:
- 📖 AAD 2023 Atopic Dermatitis Guidelines (Systemic Therapy)
- 📖 International Prurigo Nodularis Consensus
- 📖 AAAAI/ACAAI 2023 AD Practice Parameter
Nemluvio Prior Authorization Criteria
Standard criteria across major US payers for Nemluvio. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Step therapy: Dupixent (dupilumab) not tried first
- → Topical corticosteroid and calcineurin inhibitor trials not documented
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Nemluvio
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Nemluvio Prior Authorization FAQ
Why was my Nemluvio prior authorization denied?
The most common denial reasons for Nemluvio are: Step therapy: Dupixent (dupilumab) not tried first; Nodule count, IGA, or peak pruritus NRS not documented; Topical corticosteroid and calcineurin inhibitor trials not documented; Concurrent biologic or JAK inhibitor use; Prescriber is not a dermatologist.
What should a Nemluvio Letter of Medical Necessity include?
Document the diagnosis with nodule count, IGA, and worst-itch NRS for prurigo nodularis, or EASI, BSA, and IGA for atopic dermatitis. List topical corticosteroid and calcineurin inhibitor trials with potency, duration, and outcome, plus any dupilumab or JAK inhibitor history with reason for discontinuation. Explain the rationale for IL-31 targeting when itch is the dominant symptom.
Which payers cover Nemluvio?
Nemluvio is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Humana, Express Scripts, though formulary tier and prior authorization criteria vary.